DATATRAK’s Product Suite Expands Into Chinese Market Through Tigermed Partnership
DATATRAK International, Inc. announced translation of DATATRAK ONE to Simplified Chinese
feature2
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Neovasc’s Refractory Angina Treatment Receives CE Mark
Results of a published prospective three-year clinical study have demonstrated that the Reducer is safe and effective at providing relief of angina symptoms in refractory angina patients.
Wound Management Activates Orthopedic Business; Partner Chosen to Develop Products Based on its Patent
Wound Management announced that its subsidiary, Resorbable Orthopedic Products has entered into an agreement with BioStructures.
IntelGenx’s Anti-Depressant, CPI-300, Receives FDA Approval
IntelGenx is at the forefront of the industry with CPI-300 being the only single dose 450 mg formulation of Bupropion HCl approved by the FDA.
VisionCare’s FDA Approved Telescope Gets Implanted
VisionCare’s lead product, Implantable Miniature Telescope by Dr. Isaac Liphitz, enlarges images in front of the eye approximately 2.5 times their normal size.
PLC Medical Systems Uses Revenue in the EU to Fund Phase III Development in the US
Mark Tauscher, President and CEO of PLC Medical Systems Inc., discusses the company’s product RenalGuard, an important tool for ridding the body of toxins.
Hepregen Corp. Introduces Toxicity Screening Platform
Hepregen is focused on improving and commercializing its microliver platform, HepatoPac, into the drug-development pipeline of pharmaceutical and biotechnology companies.
Special Panels Present Significant Opportunity at OneMedForum SF 2012
Panels consisting of leading strategic and financial investors will be followed by short presentations by promising companies. Over 100 companies will present.
Del Mar Pharmaceuticals Plans Clinical Trials for GBM Treatment
DMP estimates that the market for treating GBM patients post front-line therapy exceeds US$200 million annually in North America.